Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL.
Campanella A, Capasso A, Heltai S, Taccetti C, Albi E, Herishanu Y, Haggenburg S, Chatzikonstantinou T, Doubek M, Kättström M, Giannopoulos K, Simkovic M, Moreno C, Massaia M, Bumbea H, Alshemmari S, Ranghetti P, Perotta E, Martini F, Sant'Antonio E, Colia M, Combi C, Levi S, Kater AP, Hazenberg M, Nijhof IS, Hofsink Q, Demosthenous C, Kotaskova J, Zaleska J, Vrbacky F, Raya AM, Bisogno D, Tripoli IE, Popov VM, Roman V, Stavroyianni N, Karypidou M, Scarano E, Locatelli M, Frenquelli M, Scarfò L, Stamatopoulos K, Ghia P. Campanella A, et al. Among authors: colia m. Am J Hematol. 2024 Apr;99(4):745-750. doi: 10.1002/ajh.27218. Epub 2024 Jan 24. Am J Hematol. 2024. PMID: 38264829
Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
Scarfò L, Heltai S, Albi E, Scarano E, Schiattone L, Farina L, Moia R, Deodato M, Ferrario A, Motta M, Reda G, Sancetta R, Coscia M, Rivela P, Laurenti L, Varettoni M, Perotta E, Capasso A, Ranghetti P, Colia M, Ghia P. Scarfò L, et al. Among authors: colia m. Blood. 2022 Dec 1;140(22):2348-2357. doi: 10.1182/blood.2022016901. Blood. 2022. PMID: 35921541 Free article.
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial.
Scarfò L, Ferrari S, Frustaci AM, Tani M, Bari A, Scarano E, Colia M, Ranghetti P, Angelillo P, Ronchi P, Ponzoni M, Ferreri AJM, Ghia P. Scarfò L, et al. Among authors: colia m. Blood Adv. 2022 Sep 27;6(18):5356-5359. doi: 10.1182/bloodadvances.2022007138. Blood Adv. 2022. PMID: 35613463 Free PMC article. Clinical Trial. No abstract available.